NewGenIvf Group Limited (NASDAQ:NIVF) Stock Short Interest Report for October

NewGenIvf Group Limited (NASDAQ:NIVF) was the target of a significant drop in short interest in October. As of October 30th, there was short interest totaling 125,342 shares, a drop of 94.9% from the October 15th total of 2,470,389 shares. Based on an average daily trading volume, of 934,259 shares, the days-to-cover ratio is currently 0.1 days. Currently, 16.5% of the shares of the stock are short sold.

Analysts Set New Price Targets

Several brokerages have commented on NIVF. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a research report on Monday, November 2nd. Wall Street Zen lowered shares of NewGenIvf Group to a “strong sell” rating in a research report on Saturday, October 24th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has an average rating of “Sell”.

NewGenIvf Group Price Performance

Shares of NASDAQ:NIVF traded down $0.12 on Tuesday, reaching $0.28. 505,898 shares of the company traded hands, compared to its average volume of 414,765. NewGenIvf Group has a fifty-two week low of $0.27 and a fifty-two week high of $8,266.75. The company’s 50 day moving average is $12.77 and its 200-day moving average is $358.26.

NewGenIvf Group (NASDAQ:NIVF) last issued its earnings results on Wednesday, October 7th. The company reported ($111.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $581.76 by ($693.30). The company had revenue of $0.96 million during the quarter, compared to analyst estimates of $20.10 million. As a group, equities analysts anticipate that NewGenIvf Group will post 1365.44 EPS for the current fiscal year.

About NewGenIvf Group

NewGenIvf Group Limited (NASDAQ:NIVF) is a fertility-services company focused on assisted reproductive technology and related medical care. Through its NewGen IVF operations, the company provides services intended to help individuals and couples pursue pregnancy, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), fertility assessments and fertility-preservation procedures. Its service offering also includes egg and sperm freezing, embryo-related services, genetic testing and donor-program support, subject to applicable medical and regulatory requirements.